5.51
-0.05(-0.90%)
Currency In USD
| Previous Close | 5.56 |
| Open | 5.42 |
| Day High | 5.55 |
| Day Low | 5.18 |
| 52-Week High | 28.6 |
| 52-Week Low | 4.2 |
| Volume | 14,592 |
| Average Volume | 705,623 |
| Market Cap | 3.88M |
| PE | -0.29 |
| EPS | -18.93 |
| Moving Average 50 Days | 8.85 |
| Moving Average 200 Days | 7.63 |
| Change | -0.05 |
If you invested $1000 in Artelo Biosciences, Inc. (ARTL) since IPO date, it would be worth $13.17 as of September 27, 2025 at a share price of $5.51. Whereas If you bought $1000 worth of Artelo Biosciences, Inc. (ARTL) shares 5 years ago, it would be worth $76.53 as of September 27, 2025 at a share price of $5.51.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms
GlobeNewswire Inc.
Sep 10, 2025 12:30 PM GMT
SOLANA BEACH, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, derm
Artelo Biosciences Announces Closing of $3.0 Million Public Offering
GlobeNewswire Inc.
Sep 05, 2025 8:05 PM GMT
SOLANA BEACH, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, derm
Artelo Biosciences Announces Pricing of $3.0 Million Public Offering
GlobeNewswire Inc.
Sep 04, 2025 12:37 PM GMT
SOLANA BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, derm